Skip to main content
. Author manuscript; available in PMC: 2011 Apr 1.
Published in final edited form as: Psychopharmacology (Berl). 2010 Feb 19;209(2):163–174. doi: 10.1007/s00213-010-1784-0

Fig. 3.

Fig. 3

EEDQ treatment inactivates 5-HT2A receptor binding (N=6) in the mouse brain which is prevented by pretreatment with MDL100907 (0.25 mg/kg, N=4), but not SB206553 (3.0 mg/kg, N=4), suggesting that 3.0 mg/kg SB206553 does not bind to 5-HT2A receptor binding sites at this dose or lower doses